CHA Biotech Co. Ltd (KQ:085660) — Market Cap & Net Worth
Market Cap & Net Worth: CHA Biotech Co. Ltd (085660)
CHA Biotech Co. Ltd (KQ:085660) has a market capitalization of $625.66 Million (₩923.23 Billion) as of June 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #11267 globally and #307 in its home market, demonstrating a 6.90% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CHA Biotech Co. Ltd's stock price ₩12080.00 by its total outstanding shares 76426183 (76.43 Million). Review 085660 liabilities breakdown to assess the company's total debt and financial obligations.
CHA Biotech Co. Ltd Market Cap History: 2015 to 2026
CHA Biotech Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $735.46 Million to $625.66 Million (-2.01% CAGR).
Index Memberships
CHA Biotech Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$270.08 Billion | 0.23% | #73 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$270.08 Billion | 0.23% | #73 of 1384 |
Weight: CHA Biotech Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CHA Biotech Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CHA Biotech Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
CHA Biotech Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $657.77 Million | $449.26 Billion | $16.88 Billion | 0.00x | 0.04x |
| 2017 | $1.17 Billion | $417.46 Billion | -$46.50 Billion | 0.00x | N/A |
| 2018 | $1.05 Billion | $488.60 Billion | $24.39 Billion | 0.00x | 0.04x |
| 2019 | $748.41 Million | $534.61 Billion | $46.37 Billion | 0.00x | 0.02x |
| 2020 | $1.04 Billion | $664.72 Billion | -$18.66 Billion | 0.00x | N/A |
| 2021 | $1.03 Billion | $727.48 Billion | -$13.97 Billion | 0.00x | N/A |
| 2022 | $673.31 Million | $844.58 Billion | -$47.54 Billion | 0.00x | N/A |
| 2023 | $1.01 Billion | $953.95 Billion | -$8.43 Billion | 0.00x | N/A |
| 2024 | $593.55 Million | $1.05 Trillion | -$8.05 Billion | 0.00x | N/A |
| 2025 | $759.80 Million | $1.27 Trillion | -$109.88 Billion | 0.00x | N/A |
Competitor Companies of 085660 by Market Capitalization
Companies near CHA Biotech Co. Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to CHA Biotech Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
CHA Biotech Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, CHA Biotech Co. Ltd's market cap moved from $735.46 Million to $ 625.66 Million, with a yearly change of -2.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩625.66 Million | -17.66% |
| 2025 | ₩759.80 Million | +28.01% |
| 2024 | ₩593.55 Million | -41.50% |
| 2023 | ₩1.01 Billion | +50.69% |
| 2022 | ₩673.31 Million | -34.84% |
| 2021 | ₩1.03 Billion | -0.50% |
| 2020 | ₩1.04 Billion | +38.75% |
| 2019 | ₩748.41 Million | -28.47% |
| 2018 | ₩1.05 Billion | -10.22% |
| 2017 | ₩1.17 Billion | +77.17% |
| 2016 | ₩657.77 Million | -10.56% |
| 2015 | ₩735.46 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of CHA Biotech Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $625.66 Million USD |
| MoneyControl | $625.66 Million USD |
| MarketWatch | $625.66 Million USD |
| marketcap.company | $625.66 Million USD |
| Reuters | $625.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CHA Biotech Co. Ltd
Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising f… Read more